Is UK Nice Angling For Influence On Drug Pricing?
No commentsBy Ed Silverman // August 26th, 2008 // 7:59 am
An unprecedented attack last week on pharmaceutical prices by the National Institute for Health and Clinical Excellence (NICE), chairman Michael Rawlins, signals a controversial new role for the UK health watchdog in the forthcoming overhaul of drugs pricing, PharmaTimes reports.
Rawlins’ comments were in part prompted by the fierce criticism NICE received for failing to approve a batch of new kidney cancer treatments. Some observers, however, say his outspoken attack was prompted by other motives.
Joe Collier, an emeritus professor of medicines policy at St George’s, University of London, tells PharmaTimes that Rawlins (pictured above) was “jockeying for a central role in price negotiation” in the forthcoming overhaul of the UK’s Pharmaceutical Price Regulation Scheme.
Monday, August 25th, 2008 at 12:00 am and is filed under drugs and pharmaceuticals. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.
Leave a reply